WuXi Biologics (Cayman) (FRA:1FW2) ROE % Adjusted to Book Value : 2.10% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) ROE % Adjusted to Book Value?

WuXi Biologics (Cayman)'s ROE % for the quarter that ended in Dec. 2023 was 5.80%. WuXi Biologics (Cayman)'s PB Ratio for the quarter that ended in Dec. 2023 was 2.76. WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 2.10%.

WuXi Biologics (Cayman) ROE % Adjusted to Book Value Historical Data

The historical data trend for WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) ROE % Adjusted to Book Value Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

1.10

0.60

1.41

2.02

3.19

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial													1.04	2.03	1.66	3.19	2.10

Competitive Comparison of WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value falls into.

WuXi Biologics (Cayman) ROE % Adjusted to Book Value Calculation

WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.80%	/	2.76
	=	3.19%

WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	5.80%	/	2.76
	=	2.10%

WuXi Biologics (Cayman) ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines